DCR

metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 -
versus pegylated liposomal doxorubicin
avelumab alone vs. pegylated liposomal doxorubicin 1 certainty unassessable+102%
avelumab plus pegylated liposomal doxorubicin vs. pegylated liposomal doxorubicin 1 certainty unassessable+179%